For roughly three years, a grey-market parallel to Ozempic and Zepbound operated openly inside the US healthcare system. Telehealth companies and compounding pharmacies sold injectable semaglutide and tirzepatide at prices of $150 to $400 per month, compared to list prices of $900 to $1,400 for the branded drugs, under a legal exemption tied to FDA drug shortage designations.
The pitch was straightforward: same active ingredient, same mechanism, fraction of the cost. Millions of patients who could not afford or access Novo Nordisk's Ozempic or Wegovy, or Eli Lilly's Zepbound or Mounjaro, used compounded versions. The question worth examining is how accurate the "same medication" framing was — and what the FDA's shortage resolution means for patients who were relying on it.
The Legal Mechanism: How Compounding Under Shortage Works
Drug compounding is the practice of preparing a customized drug product outside the standard manufacturing and approval process. It is legal and serves genuine medical needs: patients with allergies to excipients in approved products, those requiring non-standard doses, or those needing formulations that are simply not commercially available.
The shortage exemption is narrower. Under the Federal Food, Drug, and Cosmetic Act, compounders may prepare copies of commercially available drugs when those drugs appear on the FDA drug shortage list. Two categories of compounder operate under this exemption:
- 503A pharmacies — traditional compounding pharmacies operating under state pharmacy board oversight, permitted to compound for individual patients with a valid prescription.
- 503B outsourcing facilities — larger-scale operations registered with the FDA, subject to current good manufacturing practice (cGMP) inspections, permitted to produce larger batches without patient-specific prescriptions.
Semaglutide injection products entered the FDA shortage list in March 2022 (Wegovy) and August 2022 (Ozempic). Tirzepatide was added later. This shortage designation opened the door to widespread compounding.
The Shortage Timeline and the Closing Window
The shortage exemption was always intended as a temporary access bridge, not a permanent parallel market. Both drugs have since been removed from the shortage list, triggering enforcement deadlines for compounders to stop production.
Tirzepatide was first. The FDA declared the tirzepatide shortage resolved in December 2024, with 503A pharmacies required to cease compounding by around February 18, 2025 and 503B outsourcing facilities by around March 19, 2025. A federal court subsequently backed the FDA's determination in the tirzepatide case.
Semaglutide followed. On February 21, 2025, the FDA issued its declaratory order resolving the semaglutide injection shortage, having reviewed supply and demand data from Novo Nordisk for all strengths of Ozempic and Wegovy. Enforcement deadlines were April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities.
After those dates, compounding semaglutide or tirzepatide as a copy of the approved drug became generally prohibited — with a narrow exception for 503A pharmacies compounding for individual patients with a documented clinical difference from the approved product (for example, a specific dose strength or formulation not commercially available).
The Salt-Form Problem
Beyond the legal question, there is a scientific one that the marketing mostly skipped over. Approved semaglutide (Ozempic, Wegovy) uses the semaglutide base API. Many compounded versions used semaglutide sodium or semaglutide acetate — salt forms of the molecule that are not the same as the approved drug and have no clinical data establishing bioequivalence or equivalent safety.
The FDA explicitly flagged this in its compounding guidance, noting that semaglutide sodium and semaglutide acetate are not the active ingredient in any FDA-approved product and that compounding these salt forms is not covered by the shortage exemption. No head-to- head pharmacokinetic data demonstrates that a given dose of semaglutide sodium produces the same exposure or effect as the equivalent dose of base semaglutide.
Safety Signals and Dosing Risks
The FDA received a significant volume of adverse-event reports associated with compounded GLP-1 products during the shortage period. The core safety concerns were not primarily about the active ingredient itself — semaglutide and tirzepatide have established safety profiles from large randomized trials — but about the compounding context:
- Dosing errors: Compounded semaglutide and tirzepatide are typically supplied as multi-dose vials, requiring patients to draw their own dose with a syringe. This is an unfamiliar process for most patients and a documented source of 10-fold dosing errors (drawing 1 mg when 0.1 mg was intended, for example), leading to severe nausea, vomiting, and hospitalizations.
- No bioequivalence or purity testing: Unlike approved drugs, compounded products are not subject to the FDA's pre-market efficacy and purity review. Quality varies by compounder, and patients have no reliable way to verify potency.
- Unlisted additives: Some compounded formulations included additional ingredients — B vitamins, L-carnitine, lipotropic compounds — not present in approved products and not studied in combination with GLP-1 agonists.
The Claim
“Compounded semaglutide is the same medication as Ozempic for a fraction of the price.”
(Representative claim widely used in telehealth and compounding pharmacy marketing during 2022–2025.)
Brand vs. Compounded: A Comparison
| Factor | Brand (Ozempic / Wegovy / Zepbound) | 503A Compounded | 503B Compounded |
|---|---|---|---|
| FDA approval | Yes — full NDA review | No | No |
| Active ingredient verified | Yes — base API | Variable; some used salt forms | Variable; some used salt forms |
| Bioequivalence data | Yes | None | None |
| Purity / potency testing | Required pre-market | State board oversight; variable | FDA cGMP inspections |
| Pre-filled pen / auto-injector | Yes | No — vial + syringe | No — vial + syringe |
| Legal status (post-shortage) | Approved | Generally prohibited; narrow clinical-difference exception | Generally prohibited; narrow clinical-difference exception |
| Typical monthly cost (2024) | $900–$1,400 list | ~$150–$250 | ~$200–$400 |
What the Evidence Actually Shows
Compounded GLP-1 drugs were a legally sanctioned access bridge during a genuine shortage, and for many patients they provided the only realistic route to these medications. But "same medication" overstates what compounding delivers. Compounded versions lacked bioequivalence data, some used unapproved salt forms of the API, and the vial-plus-syringe format introduced dosing risks absent from auto-injector pens. The shortage exemption has closed. Patients currently using compounded GLP-1s should discuss the transition to approved products with their prescriber, including manufacturer savings programs that can substantially reduce out-of-pocket costs.
The Bottom Line
The compounded GLP-1 market was a product of a specific regulatory circumstance — a genuine drug shortage that created a legal window — not a discovery that compounding produces equivalent medicines more cheaply. Now that the window has closed, the framing matters. These were not generic equivalents in the pharmaceutical sense. They were copies of patented drugs produced under a temporary exemption, without the safety and manufacturing standards that attach to approved drugs.
For patients who benefited from access during the shortage period, that access was real and, for many, medically meaningful. The issue is the marketing language that obscured what was being sold. Patients continuing to use compounded versions after the enforcement deadlines, or sourced from operations not registered with the FDA, are operating outside the legal framework entirely — with no quality oversight at all.
Novo Nordisk and Eli Lilly both offer savings programs that can reduce costs for eligible patients. Insurance coverage, including recent Medicaid expansions for obesity treatment, has also broadened. These are the channels worth exploring for patients navigating the post-shortage landscape.
Verdict: Mixed Evidence
Compounded semaglutide and tirzepatide served a real access function during a genuine shortage. The underlying drugs have strong clinical trial evidence for weight loss and glycemic control. But compounded versions were not equivalent to approved products: no bioequivalence testing, variable API quality (some using unvalidated salt forms), and documented dosing risks from vial-and-syringe delivery. The "same medication for less" claim was an overstatement. The shortage exemption has closed, and continued compounding of these drugs is now generally prohibited. Evidence rating: 3/5 for the approved drugs; compounded versions cannot be rated equivalently.
References & Further Reading
- US Food and Drug Administration. (2025, February 21). Declaratory Order: Resolution of Shortages of Semaglutide Injection Products.
- US Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.
- US Food and Drug Administration. Compounding and the FDA: Questions and Answers.
- US Food and Drug Administration. FDA Drug Shortage Database.
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. (STEP 1 trial.)
- Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205–216. (SURMOUNT-1 trial.)
- Novo Nordisk. Ozempic (semaglutide) injection (manufacturer product page).
- Eli Lilly. Zepbound (tirzepatide) injection (manufacturer product page).
- Alston & Bird. (2025, March). FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers.